UNSPSC 51161574: Tiotropium bromide

This classification denotes an antimuscarinic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L64SXO195N. European Medicines Agency schedules Tiotropium bromide monohydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21897. Tiotropium bromide generally arises in the molecular formula C19H22NO4S2.BR.H2O. The term 'tiotropium bromide' is a European Pharmacopoeia designation. Most nations, for tariff and trade purposes, schedule tiotropium bromide under HS 29399900 and SITC 54149.

As of Q4 2014, TIOTROPIUM BROMIDE remains US FDA's Preferred Term for this commodity. Tiotropium bromide bears US NLM identifiers UMLS ID CL449040 and NCI Concept Code C84608. SMILES: C[N+]1([C@@H]2C[C@H](C[C@H]1[C@H]3[C@@H]2O3)OC(=O)C(C4CCCS4)(C5CCCS5)O)C.[BR-].

UNSPSC 51161574 Tiotropium bromide is a Commodity code covering individual pharmaceutical active ingredients and finished products sourced by state and local government healthcare and institutional purchasing cooperatives. State and local buyers use this code for branded and generic pharmaceutical procurement through established wholesaler networks, typically as part of multistate cooperative agreements that aggregate demand across participating jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) represents the primary issuing body visible in recent activity, administering contracts on behalf of participating state and local government facilities across multiple states including Minnesota and Oregon. Vendors supplying under this code must maintain cGMP certification and Drug Supply Chain Security Act (DSCSA) compliance, establish relationships with authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson), and submit detailed product specifications including National Drug Codes, SKUs, and packaging configurations. Pricing mechanisms include fixed pricing, net price formats, and WAC-minus structures, with vendors expected to absorb a 3 percent administrative fee on all contract purchases and maintain comprehensive insurance coverage including $5 million commercial general liability.

MMCAP's Generic Multi Source Pharmaceuticals and OTC Products RFP, posted January 20, 2026 with a March 26, 2026 response deadline, represents the most recent solicitation under this code. The cooperative is establishing multiple contracts effective July 1, 2026, with a two-year initial term and optional extensions, with pricing weighted at 75 percent of evaluation criteria and administrative compliance (EDI capability, data format adherence, and flat-fee agreement) accounting for the remainder. All products must be available in the marketplace by May 15, 2026, and possess expiration dates of at least one year from manufacture with minimum six-month shelf life. No specific dollar amounts, budget ranges, or set-aside designations are disclosed in the solicitation materials; MMCAP reserves discretion to make sole, dual, or multi-awards based on therapeutic considerations and member-specific needs.